高度扭矩选择性的热三烯6π电环化控制利血平型生物碱的十二氢吲哚并[2,3- a ]苯并[ g ]喹嗪骨架的C3和C18立构中心之间的相对立体化学。采用串联交叉偶联/电环化方案使我们能够形成必要的三烯并确保其随后的环化。一种新型低温二溴乙烯酮缩醛克莱森重排建立了钯催化交叉偶联反应所需的环外二烯基溴化物前体。
Copper (I) Iodide Nanoparticles on Polyaniline As a Green, Recoverable and Reusable Catalyst for Multicomponent Click Synthesis of 1,4-disubstituted-1H-1,2,3-triazoles
A one-pot procedure for the synthesis of 1,4-disubstituted-1H-1,2,3-triazole derivatives via the three component coupling reaction between terminal alkynes, benzyl halides/-halo ketones and sodium azide in the presences of CuI nanoparticles supported onto polyaniline (Nano CuI/PANI) catalyst in water has been developed. This heterogeneous catalyst showed high catalytic activity and 1,4-regioselectivity
在CuI存在下,通过末端炔烃,苄基卤化物/α-卤代酮和叠氮化钠之间的三组分偶联反应,通过一锅法合成1,4-二取代-1H-1,2,3-三唑衍生物已经开发了负载在水中的聚苯胺(Nano CuI / PANI)催化剂上的纳米颗粒。这种非均相催化剂显示出高的催化活性和1,4-区域选择性,可以在水中作为“绿色”溶剂进行点击环化,并且在所有情况下,重复进行五次实验均获得了良好或优异的收率。
[EN] PIPERAZINE THIAZOLE DERIVATIVES USEFUL IN THE TREATMENT OF TAUOPATHIES SUCH AS ALZHEIMER'S DISEASE<br/>[FR] DÉRIVÉS DE PIPÉRAZINE THIAZOLE UTILES DANS LE TRAITEMENT DES TAUOPATHIES TELLES QUE LA MALADIE D'ALZHEIMER
申请人:REMYND NV
公开号:WO2013024168A1
公开(公告)日:2013-02-21
The present invention relates to a compound of formula (IA), wherein G1 is lower alkyl; lower alkyl substituted by one or more halogens; cycloalkyl; tetrahydropyran-4-yl; phenethyl; phenethyl substituted by one or more halogens; phenoxymethyl; phenoxymethyl substituted by one or more halogens; benzyloxyethyl; benzyloxy-ethyl substituted by one or more halogens; or is -NR2R3; R2 is hydrogen or lower alkyl; R3 is lower alkyl; tetrahydropyran-4-yl; -CH2-cycloalkyl; or cycloalkyl optionally substituted by lower alkyl substituted by one or more halogens; or R2 and R3 form together with the N-atom to which they are attached a heterocycloalkyl group with 4 or 5 carbon atoms, which is optionally substituted by one or more substituents selected from halogen; or lower alkyl substituted by one or more halogens; X is -CH2- or -(CH2)2-; Ar is phenyl or pyridinyl; R4 is halogen; lower alkyl; lower alkyl substituted by one or more halogens; or lower alkoxy; n is 1 or 2; or to a pharmaceutically active salt thereof, to a stereoisomeric form, including an individual diastereoisomer or enantiomer of the compound of formula (IA) as well as to a racemic or non-racemic mixture thereof. The present invention also relates to the use of a compound of formula (IA) for treating certain neurodegenerative disorders characterized by cytotoxic TAU misfolding and/or aggregation.
<i>N</i>-Iodosuccinimide-Mediated Dimerization of 2-Alkynylnaphthols: A Highly Diastereoselective Construction of Bridged Polycyclic Compounds via Vinylidene <i>ortho</i>-Quinone Methide Intermediate
作者:Yu Tan、Zhengxing Zhao、Zhili Chen、Shengli Huang、Shiqi Jia、Lei Peng、Da Xu、Wenling Qin、Hailong Yan
DOI:10.1021/acs.orglett.0c01458
日期:2020.6.5
2-alkynylnaphthols is presented to furnish bridged polycycliccompounds containing a bicyclo[3.2.1]octane moiety with good to excellent yields. The reaction proceeded under mild conditions using N-iodosuccinimide as a promoter, simultaneously constructing one new C–O bond and two new C–C bonds. A tetra-substituted vinylidene ortho-quinone methideintermediate was likely involved, and the steric hindrance
Phosphorus-containing HMG-COA reductase inhibitors, new intermediates
申请人:E. R. Squibb & Sons, Inc.
公开号:US05276021A1
公开(公告)日:1994-01-04
Compounds which are useful as inhibitors of cholesterol biosynthesis and thus as hypocholesterolemic agents are provided which have the structure ##STR1## wherein R is OH, or salts thereof or lower alkoxy; R.sup.x is H or alkyl; X is --CH.sub.2 --, --CH.sub.2 --CH.sub.2 --, --CH.dbd.CH--, --C.tbd.C--, --CH.sub.2 CH.sub.2 CH.sub.2 -- or --CH.sub.2 O-- (where O is linked to Z); Z is a hydrophobic anchor, such as ##STR2## wherein the dotted lines represent optional double bonds.
Phosphorus-containing HMG-CoA reductase inhibitors, new intermediates
申请人:E. R. Squibb & Sons, Inc.
公开号:US05091378A1
公开(公告)日:1992-02-25
Compounds which are useful as inhibitors of cholesterol biosynthesis and thus as hypocholesteroleumic agents are provided which have the structure ##STR1## wherein R is OH, or salts thereof or lower alkoxy; R.sup.x is H or alkyl; X is --CH.sub.2 --, --CH.sub.2 --CH.sub.2 --, --CH.dbd.CH--, --C.tbd.C--, --CH.sub.2 CH.sub.2 CH.sub.2 -- or --CH.sub.2 O-- (where O is linked to Z); Z is a hydrophobic anchor, such as ##STR2## wherein the dotted lines represent optional double bonds. New intermediates used in preparing the above compounds, pharmaceutical compositions containing such compounds and a method for using such compounds to inhibit cholesterol biosynthesis are also provided.